You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluphenazine
Accession NumberDB00623  (APRD00633)
TypeSmall Molecule
GroupsApproved
DescriptionA phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine. [PubChem]
Structure
Thumb
Synonyms
1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine
10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine
10-(3'-(4''-(beta-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine
2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol
2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine
4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol
4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
Flufenazina
Fluorfenazine
Fluorophenazine
Fluorphenazine
Fluphenazin
Fluphénazine
Fluphenazinum
Triflumethazine
External Identifiers
  • SQ 10733
  • Squibb 16144
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluphenazinetablet2 mgoralAa Pharma Inc1977-12-31Not applicableCanada
Fluphenazinetablet1 mgoralAa Pharma Inc1977-12-31Not applicableCanada
Fluphenazinetablet5 mgoralAa Pharma Inc1977-12-31Not applicableCanada
Fluphenazine 1 Tab 1mgtablet1 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine 2 Tab 2mgtablet2 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine 5 Tab 5mgtablet5 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine Decanoate Injection B.P.liquid25 mgintramuscular; subcutaneousHospira Healthcare CorporationNot applicableNot applicableCanada
Fluphenazine Decanoate Injection B.P.liquid100 mgintramuscular; subcutaneousHospira Healthcare CorporationNot applicableNot applicableCanada
Fluphenazine Decanoate Injection, USPsolution25 mgintramuscular; subcutaneousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Fluphenazine Omegaliquid25 mgintramuscular; subcutaneousOmega Laboratories Ltd1999-05-28Not applicableCanada
Fluphenazine Omegaliquid100 mgintramuscular; subcutaneousOmega Laboratories Ltd2000-11-20Not applicableCanada
Modecate Concentrateliquid100 mgintramuscular; subcutaneousBristol Myers Squibb Canada1990-12-31Not applicableCanada
Modecate Inj 25mg/mlliquid25 mgintramuscularSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1976-12-312004-08-05Canada
Moditen Enanthate Inj 25mg/mlliquid25 mgintramuscularSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1968-12-312003-07-28Canada
Moditen HCl Tab 10mgtablet10 mgoralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1985-12-312003-07-28Canada
PMS Fluphenazine Tab 1mgtablet1 mgoralPharmascience Inc1992-12-31Not applicableCanada
PMS Fluphenazine Tab 2mgtablet2 mgoralPharmascience Inc1992-12-31Not applicableCanada
PMS Fluphenazine Tab 5mgtablet5 mgoralPharmascience Inc1992-12-31Not applicableCanada
PMS-fluphenazine Decanoateliquid100 mgintramuscular; subcutaneousPharmascience Inc2000-08-31Not applicableCanada
PMS-fluphenazine Decanoate Inj (bp) 25mg/mlliquid25 mgintramuscular; subcutaneousPharmascience Inc1994-12-31Not applicableCanada
PMS-fluphenazine Elixir 0.5mg/mlelixir.5 mgoralPharmascience Inc1996-10-162008-11-07Canada
Rho-fluphenazine Decanoate Inj-25mg/ml Im Scsolution25 mgintramuscular; subcutaneousRhodiapharm Inc1996-11-282004-07-30Canada
Rho-fluphenazine Decanoate Inj.conc-100mg/mlsolution100 mgintramuscular; subcutaneousRhodiapharm Inc1996-11-282004-07-30Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Fluphenazine Tab 2.5mgtablet2.5 mgoralApotex Inc1977-12-31Not applicableCanada
Apo-fluphenazine Injectableliquid25 mgintramuscular; subcutaneousApotex Inc2001-10-052013-08-02Canada
Fluphenazine Decanoateinjection, solution25 mg/mLintramuscular; subcutaneousAPP Pharmaceuticals, LLC2010-12-15Not applicableUs
Fluphenazine Decanoateinjection, solution25 mg/mLintramuscular; subcutaneousPar Pharmaceutical, Inc.2014-07-09Not applicableUs
Fluphenazine Decanoateinjection, solution25 mg/mLintramuscular; subcutaneousTYA Pharmaceuticals2010-12-15Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2011-10-25Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralTYA Pharmaceuticals1987-10-16Not applicableUs
Fluphenazine Hydrochloridesolution, concentrate5 mg/mLoralPharmaceutical Associates, Inc.2010-09-01Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralSandoz Inc1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralMylan Institutional Inc.1998-07-15Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet2.5 mg/1oralREMEDYREPACK INC.2011-06-03Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralMylan Institutional Inc.1998-04-30Not applicableUs
Fluphenazine Hydrochlorideinjection, solution2.5 mg/mLintramuscularTYA Pharmaceuticals2010-12-28Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine Hydrochlorideelixir.5 mg/mLoralPharmaceutical Associates, Inc.2010-08-31Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-09-26Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralSandoz Inc1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralREMEDYREPACK INC.2010-12-23Not applicableUs
Fluphenazine Hydrochlorideinjection, solution2.5 mg/mLintramuscularAPP Pharmaceuticals, LLC2010-12-28Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralAmerican Health Packaging2014-10-13Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralMylan Institutional Inc.1998-06-02Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet1 mg/1oralREMEDYREPACK INC.2011-08-02Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralSandoz Inc1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet1 mg/1oralREMEDYREPACK INC.2011-07-11Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2016-04-11Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralMylan Institutional Inc.1998-06-04Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2010-12-23Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralSandoz Inc1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnatensolBristol-Myers Squibb
Dapotum DNot Available
FludecasinTanabe Mitsubishi Pharma
FludecateRafa
FlumezinTanabe Mitsubishi Pharma
FunazineJohnson
LyogenLundbeck
Lyogen DepotLundbeck
Lyogen RetardLundbeck
MetotenHemofarm
ModecateBristol-Myers Squibb
ModitenBristol-Myers Squibb
Moditen DepoKrka
PermitilNot Available
ProlixinBristol-Myers Squibb
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fluphenazine decanoate
5002-47-1
Thumb
  • InChI Key: VIQCGTZFEYDQMR-UHFFFAOYSA-N
  • Monoisotopic Mass: 591.310632972
  • Average Mass: 591.771
DBSALT000776
Fluphenazine dihydrochloride
146-56-5
Thumb
  • InChI Key: MBHNWCYEGXQEIT-UHFFFAOYSA-N
  • Monoisotopic Mass: 509.128223252
  • Average Mass: 510.443
DBSALT000288
Fluphenazine enanthate
2746-81-8
Thumb
  • InChI Key: LRWSFOSWNAQHHW-UHFFFAOYSA-N
  • Monoisotopic Mass: 549.26368278
  • Average Mass: 549.691
DBSALT000777
Fluphenazine hydrochloride
ThumbNot applicableDBSALT001197
Categories
UNIIS79426A41Z
CAS number69-23-8
WeightAverage: 437.522
Monoisotopic: 437.174867774
Chemical FormulaC22H26F3N3OS
InChI KeyInChIKey=PLDUPXSUYLZYBN-UHFFFAOYSA-N
InChI
InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
IUPAC Name
2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethan-1-ol
SMILES
OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • N-alkylpiperazine
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Thioether
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor management of manifestations of psychotic disorders.
PharmacodynamicsFluphenazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Fluphenazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of actionFluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9837
Blood Brain Barrier+0.975
Caco-2 permeable-0.5387
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor IInhibitor0.923
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.7669
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.7091
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.937
CYP450 3A4 inhibitorNon-inhibitor0.715
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7056
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8828
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8990 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9146
hERG inhibition (predictor II)Inhibitor0.8157
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Teva parenteral medicines inc
  • Bristol myers squibb co
  • Apothecon inc div bristol myers squibb
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Lannett holdings inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral2.5 mg
Injection, solutionintramuscular; subcutaneous25 mg/mL
Elixiroral.5 mg/mL
Injection, solutionintramuscular2.5 mg/mL
Solution, concentrateoral5 mg/mL
Tabletoral1 mg/1
Tabletoral2.5 mg/1
Tabletoral5 mg/1
Tablet, film coatedoral1 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral2.5 mg/1
Tablet, film coatedoral5 mg/1
Liquidintramuscular; subcutaneous100 mg
Liquidintramuscular25 mg
Tabletoral10 mg
Tabletoral1 mg
Tabletoral2 mg
Tabletoral5 mg
Liquidintramuscular; subcutaneous25 mg
Elixiroral.5 mg
Solutionintramuscular; subcutaneous25 mg
Solutionintramuscular; subcutaneous100 mg
Prices
Unit descriptionCostUnit
Fluphenazine Omega 100 mg/ml31.2USD ml
Modecate Concentrate 100 mg/ml31.2USD ml
Pms-Fluphenazine Decanoate 100 mg/ml31.2USD ml
Fluphenazine Decanoate 25 mg/ml Solution14.0USD ml
Fluphenazine 2.5 mg/ml vial7.82USD ml
Fluphenazine Omega 25 mg/ml5.22USD ml
Prolixin 10 mg tablet3.1USD tablet
Prolixin 5 mg tablet2.38USD tablet
Fluphenazine dec 25 mg/ml vial1.92USD ml
Prolixin 2.5 mg tablet1.63USD tablet
Fluphenazine 10 mg tablet1.25USD tablet
Fluphenazine HCl 10 mg tablet1.19USD tablet
Fluphenazine 5 mg tablet0.97USD tablet
Fluphenazine HCl 5 mg tablet0.94USD tablet
Fluphenazine 2.5 mg tablet0.84USD tablet
Fluphenazine HCl 2.5 mg tablet0.79USD tablet
Fluphenazine 1 mg tablet0.55USD tablet
Fluphenazine HCl 1 mg tablet0.52USD tablet
Apo-Fluphenazine 2 mg Tablet0.24USD tablet
Apo-Fluphenazine 1 mg Tablet0.18USD tablet
Apo-Fluphenazine 5 mg Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point224-226 (Salt)U.S. Patent 3,058,979
boiling point268-274 °C at 5.00E-01 mm HgPhysProp
water solubility31.1 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.36HANSCH,C ET AL. (1995)
logS-4.15ADME Research, USCD
pKa7.9EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.019 mg/mLALOGPS
logP4.4ALOGPS
logP3.97ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.95 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity117.27 m3·mol-1ChemAxon
Polarizability44.92 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.44 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-2391100000-6928faa0b341426b2c11View in MoNA
References
Synthesis Reference

Ullyot, G.E.; U.S. Patent 3,058,979; October 16, 1962; assigned to Smith Kline & French
Laboratories.

US3058979
General ReferencesNot Available
External Links
ATC CodesN05AB02
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineFluphenazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineFluphenazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Fluphenazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Fluphenazine can be decreased when combined with Abiraterone.
AcebutololFluphenazine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Fluphenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Fluphenazine.
adipiplonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fluphenazine.
AgomelatineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Fluphenazine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Alfaxalone.
AlfentanilFluphenazine may increase the hypotensive activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fluphenazine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Fluphenazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluphenazine.
AlphacetylmethadolFluphenazine may increase the hypotensive activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fluphenazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluphenazine.
AlprenololFluphenazine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Fluphenazine.
AmiodaroneThe metabolism of Fluphenazine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluphenazine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Fluphenazine.
AmobarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amobarbital.
AmodiaquineThe serum concentration of Fluphenazine can be increased when it is combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amperozide.
AmphetamineFluphenazine may decrease the stimulatory activities of Amphetamine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Fluphenazine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Fluphenazine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluphenazine.
ArotinololFluphenazine may increase the hypotensive activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluphenazine.
ArtemetherThe serum concentration of Fluphenazine can be increased when it is combined with Artemether.
ArtesunateThe serum concentration of Fluphenazine can be increased when it is combined with Artesunate.
ArticaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Asenapine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Fluphenazine.
AtenololFluphenazine may increase the hypotensive activities of Atenolol.
AtomoxetineThe metabolism of Fluphenazine can be decreased when combined with Atomoxetine.
AtovaquoneThe serum concentration of Fluphenazine can be increased when it is combined with Atovaquone.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Fluphenazine.
AzaperoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Azaperone.
AzelastineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluphenazine.
BaclofenThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Barbital.
BefunololFluphenazine may increase the hypotensive activities of Befunolol.
BenzocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Benzocaine.
BenzphetamineFluphenazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Fluphenazine.
BetaxololFluphenazine may increase the hypotensive activities of Betaxolol.
BetaxololThe metabolism of Fluphenazine can be decreased when combined with Betaxolol.
BevantololFluphenazine may increase the hypotensive activities of Bevantolol.
BezitramideFluphenazine may increase the hypotensive activities of Bezitramide.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololFluphenazine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Fluphenazine.
BopindololFluphenazine may increase the hypotensive activities of Bopindolol.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fluphenazine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluphenazine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
BrimonidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluphenazine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Fluphenazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brotizolam.
BufuralolFluphenazine may increase the hypotensive activities of Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluphenazine.
BupranololFluphenazine may increase the hypotensive activities of Bupranolol.
BuprenorphineFluphenazine may increase the hypotensive activities of Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fluphenazine.
BupropionThe metabolism of Fluphenazine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluphenazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluphenazine.
ButacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butethal.
ButorphanolFluphenazine may increase the hypotensive activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluphenazine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Fluphenazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluphenazine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Fluphenazine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Fluphenazine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Fluphenazine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Fluphenazine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluphenazine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Carbinoxamine.
CarfentanilFluphenazine may increase the hypotensive activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fluphenazine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Fluphenazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Carisoprodol.
CarteololFluphenazine may increase the hypotensive activities of Carteolol.
CarvedilolFluphenazine may increase the hypotensive activities of Carvedilol.
CelecoxibThe metabolism of Fluphenazine can be decreased when combined with Celecoxib.
CeliprololFluphenazine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Fluphenazine.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fluphenazine.
CetirizineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluphenazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Fluphenazine can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorphenamine.
ChlorphentermineFluphenazine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Fluphenazine.
ChlorpromazineThe metabolism of Fluphenazine can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Fluphenazine can be decreased when combined with Cholecalciferol.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Fluphenazine.
CimetidineThe metabolism of Fluphenazine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Fluphenazine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluphenazine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Fluphenazine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Fluphenazine.
CitalopramThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Fluphenazine.
ClemastineThe metabolism of Fluphenazine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Fluphenazine.
ClobazamThe metabolism of Fluphenazine can be decreased when combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Fluphenazine.
ClomipramineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Fluphenazine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluphenazine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Fluphenazine.
ClorazepateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clorazepate.
ClotrimazoleThe metabolism of Fluphenazine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Fluphenazine.
ClozapineThe metabolism of Fluphenazine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Fluphenazine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Fluphenazine.
CocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cocaine.
CodeineFluphenazine may increase the hypotensive activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fluphenazine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fluphenazine.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fluphenazine.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Fluphenazine.
CyclizineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluphenazine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Fluphenazine.
CyproheptadineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fluphenazine.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Fluphenazine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Fluphenazine.
DantroleneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Fluphenazine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluphenazine.
DapoxetineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dapoxetine.
DapsoneThe serum concentration of Fluphenazine can be increased when it is combined with Dapsone.
DarifenacinThe metabolism of Fluphenazine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Fluphenazine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Fluphenazine.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Fluphenazine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Fluphenazine.
DelavirdineThe metabolism of Fluphenazine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fluphenazine.
DesloratadineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluphenazine.
DetomidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Detomidine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Fluphenazine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexmedetomidine.
DextroamphetamineFluphenazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluphenazine.
DextromoramideFluphenazine may increase the hypotensive activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fluphenazine.
DextropropoxypheneFluphenazine may increase the hypotensive activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluphenazine.
DezocineFluphenazine may increase the hypotensive activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fluphenazine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Fluphenazine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluphenazine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluphenazine.
DifenoxinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Fluphenazine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fluphenazine.
DihydrocodeineFluphenazine may increase the hypotensive activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluphenazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluphenazine.
DihydroetorphineFluphenazine may increase the hypotensive activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluphenazine.
DihydromorphineFluphenazine may increase the hypotensive activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluphenazine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Fluphenazine.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Fluphenazine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Fluphenazine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Diphenhydramine.
DiphenoxylateFluphenazine may increase the hypotensive activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluphenazine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Fluphenazine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Fluphenazine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Fluphenazine.
DoramectinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluphenazine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fluphenazine.
DoxycyclineThe serum concentration of Fluphenazine can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
DoxylamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Doxylamine.
DPDPEFluphenazine may increase the hypotensive activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Fluphenazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
DronedaroneThe metabolism of Fluphenazine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Fluphenazine.
DrotebanolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fluphenazine.
DyclonineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Fluphenazine is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fluphenazine.
EfavirenzThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluphenazine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Fluphenazine.
EliglustatThe metabolism of Fluphenazine can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluphenazine.
EntacaponeThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Entacapone.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Fluphenazine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluphenazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluphenazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluphenazine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Fluphenazine.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Fluphenazine.
EscitalopramThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Escitalopram.
EsmololFluphenazine may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Fluphenazine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Fluphenazine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Fluphenazine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluphenazine.
EthanolFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluphenazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluphenazine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fluphenazine.
EthosuximideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl loflazepate.
EthylmorphineFluphenazine may increase the hypotensive activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluphenazine.
EtidocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluphenazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Fluphenazine.
EtorphineFluphenazine may increase the hypotensive activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fluphenazine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fluphenazine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Fluphenazine.
EzogabineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fenfluramine.
FentanylFluphenazine may increase the hypotensive activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluphenazine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluphenazine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Fluphenazine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Fluphenazine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Fluphenazine.
FlibanserinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flupentixol.
FlurazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Fluphenazine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Fluphenazine.
GabapentinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Fluphenazine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Fluphenazine.
GlutethimideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Glutethimide.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Fluphenazine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Fluphenazine.
GuanfacineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Halazepam.
HalofantrineThe serum concentration of Fluphenazine can be increased when it is combined with Halofantrine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Fluphenazine.
HaloperidolThe metabolism of Fluphenazine can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Halothane.
HeroinFluphenazine may increase the hypotensive activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fluphenazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Hexobarbital.
HydrocodoneFluphenazine may increase the hypotensive activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fluphenazine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Fluphenazine.
HydromorphoneFluphenazine may increase the hypotensive activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluphenazine.
Hydroxyamphetamine hydrobromideFluphenazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe serum concentration of Fluphenazine can be increased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Fluphenazine.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Fluphenazine.
IloperidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Fluphenazine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluphenazine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Fluphenazine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Fluphenazine.
IndalpineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Indalpine.
IndenololFluphenazine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Fluphenazine.
IndinavirThe metabolism of Fluphenazine can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Fluphenazine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Fluphenazine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fluphenazine.
IsofluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Isoflurane.
IsoniazidThe metabolism of Fluphenazine can be decreased when combined with Isoniazid.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Fluphenazine.
KetamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Fluphenazine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluphenazine.
KetobemidoneFluphenazine may increase the hypotensive activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fluphenazine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Fluphenazine.
KetoconazoleThe metabolism of Fluphenazine can be decreased when combined with Ketoconazole.
LabetalolFluphenazine may increase the hypotensive activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Fluphenazine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Fluphenazine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluphenazine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Fluphenazine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fluphenazine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Fluphenazine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Fluphenazine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Fluphenazine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluphenazine.
LevobunololFluphenazine may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Fluphenazine.
Levomethadyl AcetateFluphenazine may increase the hypotensive activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluphenazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levomilnacipran.
LevorphanolFluphenazine may increase the hypotensive activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluphenazine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluphenazine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Fluphenazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Fluphenazine.
LisdexamfetamineFluphenazine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Fluphenazine.
LithiumThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lithium.
LofentanilFluphenazine may increase the hypotensive activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Fluphenazine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Fluphenazine.
LopinavirThe metabolism of Fluphenazine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluphenazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fluphenazine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Fluphenazine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluphenazine.
Lu AA21004The risk or severity of adverse effects can be increased when Fluphenazine is combined with Lu AA21004.
LumefantrineThe serum concentration of Fluphenazine can be increased when it is combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lurasidone.
MagaldrateMagaldrate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Fluphenazine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluphenazine.
MeclizineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Medetomidine.
MefloquineThe serum concentration of Fluphenazine can be increased when it is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Melperone.
MephentermineFluphenazine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluphenazine.
MequitazineFluphenazine may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Metaxalone.
MethadoneFluphenazine may increase the hypotensive activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fluphenazine.
Methadyl AcetateFluphenazine may increase the hypotensive activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fluphenazine.
MethamphetamineFluphenazine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluphenazine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fluphenazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Fluphenazine.
MetipranololFluphenazine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluphenazine.
MetoprololFluphenazine may increase the hypotensive activities of Metoprolol.
MetoprololThe metabolism of Fluphenazine can be decreased when combined with Metoprolol.
MetyrosineFluphenazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fluphenazine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Fluphenazine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluphenazine.
MilnacipranThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Fluphenazine.
MirabegronThe metabolism of Fluphenazine can be decreased when combined with Mirabegron.
MirtazapineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fluphenazine.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Fluphenazine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluphenazine.
MolindoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Molindone.
MorphineFluphenazine may increase the hypotensive activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fluphenazine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fluphenazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
NabiloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nabilone.
NadololFluphenazine may increase the hypotensive activities of Nadolol.
NalbuphineFluphenazine may increase the hypotensive activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluphenazine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fluphenazine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Fluphenazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Fluphenazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluphenazine.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Fluphenazine.
NevirapineThe metabolism of Fluphenazine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Fluphenazine.
NicardipineThe metabolism of Fluphenazine can be decreased when combined with Nicardipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Fluphenazine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Fluphenazine.
NilotinibThe metabolism of Fluphenazine can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fluphenazine.
NitrazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Fluphenazine.
NormethadoneFluphenazine may increase the hypotensive activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Fluphenazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluphenazine.
OlanzapineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Fluphenazine.
OndansetronThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ondansetron.
OpiumFluphenazine may increase the hypotensive activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Fluphenazine.
OrphenadrineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluphenazine.
OsanetantThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Fluphenazine.
OxazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxazepam.
OxprenololFluphenazine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluphenazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxybuprocaine.
OxycodoneFluphenazine may increase the hypotensive activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluphenazine.
OxymorphoneFluphenazine may increase the hypotensive activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluphenazine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Fluphenazine.
PaliperidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paliperidone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Fluphenazine.
PanobinostatThe metabolism of Fluphenazine can be decreased when combined with Panobinostat.
ParaldehydeFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fluphenazine.
ParoxetineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fluphenazine.
Peginterferon alfa-2bThe serum concentration of Fluphenazine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololFluphenazine may increase the hypotensive activities of Penbutolol.
PentazocineFluphenazine may increase the hypotensive activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluphenazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluphenazine.
PerampanelThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perphenazine.
PethidineFluphenazine may increase the hypotensive activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluphenazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluphenazine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Fluphenazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluphenazine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Phenoxyethanol.
PhentermineFluphenazine may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fluphenazine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fluphenazine.
PimozideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pimozide.
PindololFluphenazine may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fluphenazine.
PizotifenThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Fluphenazine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluphenazine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Fluphenazine.
PractololFluphenazine may increase the hypotensive activities of Practolol.
PramipexoleFluphenazine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Fluphenazine.
PrazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Fluphenazine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Fluphenazine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Fluphenazine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluphenazine.
PrilocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Prilocaine.
PrimaquineThe serum concentration of Fluphenazine can be increased when it is combined with Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fluphenazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluphenazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Fluphenazine.
ProguanilThe serum concentration of Fluphenazine can be increased when it is combined with Proguanil.
PromazineThe metabolism of Fluphenazine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fluphenazine.
ProparacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Propoxycaine.
PropranololFluphenazine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluphenazine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fluphenazine.
PSD502The risk or severity of adverse effects can be increased when Fluphenazine is combined with PSD502.
PyrimethamineThe serum concentration of Fluphenazine can be increased when it is combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Quazepam.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Fluphenazine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluphenazine.
QuinacrineThe serum concentration of Fluphenazine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluphenazine.
QuinidineThe serum concentration of Fluphenazine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Fluphenazine can be increased when it is combined with Quinine.
RadicicolThe serum concentration of Fluphenazine can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ramelteon.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Fluphenazine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fluphenazine.
RanolazineThe metabolism of Fluphenazine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluphenazine.
RemifentanilFluphenazine may increase the hypotensive activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluphenazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluphenazine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Fluphenazine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluphenazine.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Fluphenazine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fluphenazine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Fluphenazine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluphenazine.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Fluphenazine.
RitonavirThe metabolism of Fluphenazine can be decreased when combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Fluphenazine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fluphenazine.
RolapitantThe metabolism of Fluphenazine can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Fluphenazine.
RomifidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Romifidine.
RopiniroleFluphenazine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Fluphenazine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluphenazine.
RotigotineFluphenazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluphenazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Fluphenazine is combined with S-Ethylisothiourea.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Fluphenazine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Fluphenazine.
ScopolamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluphenazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fluphenazine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Fluphenazine.
SertindoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sevoflurane.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fluphenazine.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Fluphenazine.
SinefunginThe serum concentration of Fluphenazine can be increased when it is combined with Sinefungin.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Fluphenazine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Fluphenazine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Fluphenazine.
SotalolFluphenazine may increase the hypotensive activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Fluphenazine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Fluphenazine.
StiripentolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Stiripentol.
SufentanilFluphenazine may increase the hypotensive activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluphenazine.
SulfadoxineThe serum concentration of Fluphenazine can be increased when it is combined with Sulfadoxine.
SulfametopyrazineThe serum concentration of Fluphenazine can be increased when it is combined with Sulfametopyrazine.
SulpirideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Fluphenazine.
SuvorexantThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Fluphenazine.
tafenoquineThe serum concentration of Fluphenazine can be increased when it is combined with tafenoquine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Fluphenazine.
TapentadolFluphenazine may increase the hypotensive activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Fluphenazine.
TasimelteonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Fluphenazine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fluphenazine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fluphenazine.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Fluphenazine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluphenazine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Fluphenazine.
TerbinafineThe metabolism of Fluphenazine can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluphenazine.
TetracaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetrodotoxin.
ThalidomideFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fluphenazine.
ThiamylalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Fluphenazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluphenazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Fluphenazine.
TiclopidineThe metabolism of Fluphenazine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tiletamine.
TimololFluphenazine may increase the hypotensive activities of Timolol.
TipranavirThe metabolism of Fluphenazine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tolcapone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Fluphenazine.
TopiramateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fluphenazine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Fluphenazine.
TramadolFluphenazine may increase the hypotensive activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluphenazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluphenazine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Fluphenazine.
TrazodoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluphenazine.
TrimethoprimThe serum concentration of Fluphenazine can be increased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluphenazine.
TriprolidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Fluphenazine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Fluphenazine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fluphenazine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Fluphenazine.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Fluphenazine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Fluphenazine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Fluphenazine.
VigabatrinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Fluphenazine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fluphenazine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Fluphenazine.
VortioxetineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Fluphenazine.
ZimelidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zimelidine.
ZiprasidoneThe metabolism of Fluphenazine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluphenazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fluphenazine.
ZonisamideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  2. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993 Dec;88(6):395-402. [PubMed:7508675 ]
  3. Qin ZH, Weiss B: Dopamine receptor blockade increases dopamine D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra. Eur J Pharmacol. 1994 Sep 15;269(1):25-33. [PubMed:7828655 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Van Kampen JM, Stoessl AJ: Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia. Neuroscience. 2000;101(3):629-35. [PubMed:11113312 ]
  3. Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999 Nov;56(5):989-96. [PubMed:10531405 ]
  4. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Mongin AA, Cai Z, Kimelberg HK: Volume-dependent taurine release from cultured astrocytes requires permissive [Ca(2+)](i) and calmodulin. Am J Physiol. 1999 Oct;277(4 Pt 1):C823-32. [PubMed:10516112 ]
  2. Kawai M, Nakashima A, Ueno M, Ushimaru T, Aiba K, Doi H, Uritani M: Fission yeast tor1 functions in response to various stresses including nitrogen starvation, high osmolarity, and high temperature. Curr Genet. 2001 May;39(3):166-74. [PubMed:11409178 ]
  3. Edlind T, Smith L, Henry K, Katiyar S, Nickels J: Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbiol. 2002 Oct;46(1):257-68. [PubMed:12366848 ]
  4. Nakabayashi H, Komada H, Yoshida T, Takanari H, Izutsu K: Lymphocyte calmodulin and its participation in the stimulation of T lymphocytes by mitogenic lectins. Biol Cell. 1992;75(1):55-9. [PubMed:1515867 ]
  5. Kauss H: Sensing of volume changes by poterioochromonas involves a ca-regulated system which controls activation of isofloridoside-phosphate synthase. Plant Physiol. 1981 Aug;68(2):420-4. [PubMed:16661928 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23